HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 20, 14906-14915, May 18, 2007

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 282/20/14906    most recent M611739200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Su, G. Articles by Friedl, A. Search for Related Content PubMed PubMed Citation Articles by Su, G. Articles by Friedl, A. Social Bookmarking                      What's this?

Shedding of Syndecan-1 by Stromal Fibroblasts Stimulates Human Breast Cancer Cell Proliferation via FGF2 Activation^*

Gui Su, Stacy A. Blaine, Dianhua Qiao, and Andreas Friedl¹

From the Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison and Pathology and Laboratory Medicine Service, Department of Veterans Affairs Medical Center, Madison, Wisconsin 53705

The cell surface heparan sulfate proteoglycan syndecan-1 is induced in stromal fibroblasts of breast carcinomas and participates in a reciprocal feedback loop, which stimulates carcinoma cell growth in vitro and in vivo. To define the molecular mechanism of carcinoma growth stimulation, a three-dimensional co-culture model was developed that combines T47D breast carcinoma cells with immortalized human mammary fibroblasts in collagen gels. By silencing endogenous syndecan-1 induction with short interfering RNA and expressing mutant murine syndecan-1 constructs, it was determined that carcinoma cell mitogenesis required proteolytic shedding of syndecan-1 from the fibroblast surface. The paracrine growth signal was mediated by the syndecan-1 heparan lfate chains rather than the ectodomain of the core protein and required fibroblast growth factor 2 and stroma-derived factor 1. This paracrine pathway may provide an opportunity for the therapeutic disruption of stromaepithelial signaling.

Received for publication, December 21, 2006

^* This work was supported by Susan G. Komen Foundation Grant BCTR0402969 and National Institutes of Health Grant R01CA107012-01A1. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Tables 1 and 2.

¹ To whom correspondence should be addressed: Dept. of Pathology and Laboratory Medicine, Clinical Sciences Center K4/812, University of Wisconsin-Madison, 600 Highland Ave., Madison, WI 53792-8550. Tel.: 608-265-9283; Fax: 608-265-6215; E-mail: afriedl{at}wisc.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. Sauer, N. Schneiderhan-Marra, C. Kazmaier, K. Hutzel, K. Koretz, R. Muche, R. Kreienberg, T. Joos, and H. Deissler Prediction of Nodal Involvement in Breast Cancer Based on Multiparametric Protein Analyses from Preoperative Core Needle Biopsies of the Primary Lesion Clin. Cancer Res., June 1, 2008; 14(11): 3345 - 3353. [Abstract] [Full Text] [PDF]